Citations

Showing 10 of 108162 citations.

Improving Time to Palliative Care Review With Predictive Modeling: Study Protocol for a Stepped-wedge, Pragmatic Randomized Controlled Trial
Wilson, Patrick M. , Ramar, Priya , Storlie, Curtis B. , Strand, Jacob J. , Morgan, Alisha, Asai, Shusaku , Ebbert, Jon O. , Soleimani, Jalal , Pickering, Brian W. , Philpot, Lindsey M. , Herasevich, Vitaly

Mayo Clinic

No container title available | March 25, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-55430/v1 Get It

Abstract Background: Palliative care is a medical specialty centered on improving the quality of life (QOL) of patients with complex or life-threatening illnesses. The need for Palliative care is increasing and with that the rigorous testing of triage tools that can be used quickly and reliably to identify patients that may benefit from palliative care. Methods: To that Aim we will conduct a two-armed stepped-wedge cluster randomized trial rolled out to two inpatient hospitals to evaluate whether a machine learning algorithm accurately identifies patients who may benefit from a comprehensive review by a palliative care specialist, and decreases time to receiving a palliative care consult in hospital. This is a single-center study which will be conducted from August 2019 to November 2020 at Saint Mary’s Hospital & Methodist Hospital, Mayo Clinic, Rochester, Minnesota. Clusters will be nursing units which will be chosen to be a mix of complex patients from Cardiology, Critical Care and Oncology and had previously established relationships with palliative medicine. The stepped wedge design will have 12 units allocated to a design matrix of 5 treatment wedges. Each wedge will last 75 days resulting in a study period of 12 months unless otherwise specified. Data will be analyzed with Bayesian hierarchical models with credible intervals denoting statistical significance.Discussion: This intervention offers a pragmatic approach to delivering specialty palliative care to hospital patients in need using machine learning, thereby leading to high value care and improved outcomes. It is not enough for AI to be utilized by simply publishing research showing predictive performance; Clinical trials demonstrating better outcomes are critically needed. Furthermore, the deployment of an AI algorithm is a complex process that requires multiple teams with varying skill sets. To evaluate a deployed AI, a pragmatic clinical trial can accommodate the difficulties of clinical practice whilst retaining scientific rigor.Trial registration NCT03976297 (ClinicalTrials.gov), registered on June 6, 2019 prior to trial start.
MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study
Chen, John J. , Pineles, Stacy L., Repka, Michael X. , Pittock, Sean J. , Henderson, Robert J. , Liu, Grant T. , (PEDIG), Pediatric Eye Disease Investigator Group, Heidary, Gena , Pittock, S J , Chen, John J , (PEDIG), Pediatric Eye Disease Investigator Group

Mayo Clinic

JAMA Ophthalmology | March 25, 2021 | Volume: 139 | Issue: 5 | Pages: 583

10.1001/jamaophthalmol.2021.0349 | PMID 33764379 Get It

Post‐arthroscopic Subchondral Insufficiency Fractures of the Knee Yield High Rate of Conversion to Arthroplasty
Barras, Laurel A. , Pareek, Ayoosh , Parkes, Chad W. , Song, Bryant M. , Saris, Daniël B.F. , Stuart, Michael D. , Krych, Aaron J. , Krych, Aaron J , Camp, Christopher L.

Mayo Clinic

Arthroscopy | March 25, 2021 | Volume: 37 | Issue: 8 | Pages: 2545-2553

10.1016/j.arthro.2021.03.029 | PMID 33774060 Get It

Purpose To evaluate both the potential causes and resultant outcomes in patients in whom subchondral insufficiency fracture of the knee (SIFK) develops after arthroscopy. Methods We performed a retrospective review of all patients with a magnetic resonance imaging diagnosis of SIFK after arthroscopic meniscectomy and chondroplasty over a 12‐year period. Results A total of 28 patients were included, with a mean age of 61 years and mean follow‐up period of 5.7 years. SIFK showed a predilection for the medial compartment (n = 25, 89%), specifically the medial femoral condyle (n = 21, 75%). In 7 patients (25%), SIFK developed in both the femoral condyle and tibial plateau in the ipsilateral compartment. Fifteen patients (54%) went on to conversion to arthroplasty at a mean of 0.72 years. The rate of survival free of conversion to arthroplasty was 57%, 45%, and 40% at 1 year, 2 years, and 5 years, respectively. Furthermore, 63% of patients with a meniscal tear and SIFK in the same compartment went on to arthroplasty ( P = .04). There was an increased risk of conversion to arthroplasty if SIFK was present in both the femur and tibia in the same compartment ( P = .04). A higher Kellgren‐Lawrence grade at the time of the SIFK diagnosis increased the likelihood of eventual arthroplasty ( P = .03). The presence of SIFK in both the femur and tibia in the ipsilateral compartment, an increased Kellgren‐Lawrence grade, and a meniscal tear or prior meniscectomy in the same compartment as SIFK were associated with an increased risk of eventual arthroplasty. Conclusions Post‐arthroscopic SIFK most commonly occurs in the medial compartment, particularly in patients who underwent a prior meniscectomy. The presence of meniscal root and radial tears in these patients is notable (75%). Ultimately, there is a high rate of progression of arthrosis (33%) and eventual conversion to arthroplasty. Level of Evidence Level IV, case series.
DDRE-33. MELATONIN AS A MASTER METABOLIC SWITCH FOR GLIOBLASTOMA
Vazquez-Ramos, Carla , Bechtle, Alexandra , Suárez-Meade, Paola , Qosja, Neda, Quiñones‐Hinojosa, Alfredo , Fernández-Gil, Beatriz I. , Schiapparelli, Paula , Sarabia-Estrada, Rachel , Escames, Germaine

Mayo Clinic

Neuro-Oncology Advances | March 25, 2021 | Volume: 3 | Issue: Supplement_1 | Pages: i13-i14

10.1093/noajnl/vdab024.055 Get It

Abstract Glioblastoma (GBM) is the most common form of malignant primary brain cancer in adults with a median survival of only 15 months. Therefore, new therapies to suppress malignant brain cancer are needed. Brain Tumor Initiating Cells (BTICs) are a GBM subpopulation of cells with a highly glycolytic profile that are thought to be responsible of the resistance of GBM to treatments. Metabolic reprogramming allows tumor cells to survive in unsupportive microenvironments. Manipulating tumor metabolism to counteract GBM resistance arises as a powerful approach with minimum effects in normal counterparts. At pharmacological concentrations, melatonin displays oncostatic properties. This is thought to be due to an increase in mitochondrial oxidative phosphorylation through the effects of melatonin in mitochondria, key organelle in metabolic homeostasis. We hypothesize that melatonin could alter BTIC metabolism, by inducing an anti-Warburg effect and as consequence, melatonin will decrease the viability of GBM cells and tumor growth. We found that treatment of GBM cell lines with 3mM melatonin significantly altered tumor cell metabolism. We observed that melatonin downregulated the lactate symporter MCT4 (p<0.002), inducing a significant intracellular accumulation of lactate (p<0.002) while decreasing it in the extracellular media (p<0.001). This was followed by a decrease in the internal pH (p<0.002). These effects were compensated by an increase in the oxygen consumption rate (OCR) followed by decay that leaded to an increase in ROS production (p<0.001). All these changes result in a depletion of cellular ATP (p<0.001) and eventually drove to a decrease in the proliferation (p<0.001) and cell death (p<0.001). When applied in vivo we observed a significant reduction in the tumor growth (p<0.001), volume (p<0.002) and weight (p<0.002), as well as a drop in the proliferation marker ki67 (p<0.001) and a fibrosis increase in treated tumors. These results position melatonin as a strong therapeutic candidate for GBM therapy.
BIMG-20. METABOLIC BIOMARKERS IN MICRODIALYSATE OF IDH-1 MUTANT TUMORS
Jacobs, Joshua , Olson, Ian , Hainy, Matthew, Oh, Ju‐Hee , Elmquist, William F. , Rajani, Karishma , Carlstrom, Lucas P. , Schroeder, Mark A. , Hainy, M., Sarkaria, Jann N. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | March 25, 2021 | Volume: 3 | Issue: Supplement_1 | Pages: i5-i5

10.1093/noajnl/vdab024.019 Get It

Abstract Glioblastoma (GBM) is a common deadly malignant brain cancer of the central nervous system, with a median survival of 12–15 months. Scientific advancements are lacking in developing effective therapies for both primary GBM, as well as secondary GBMs, that typically originate as malignant transformation of lower-grade isocitrate dehydrogenase (IDH) 1-mutant tumors. The unique metabolomic profile of IDH1-mutant tumors presents opportunities to develop biomarker signatures of therapeutic efficacy. Microdialysis is an extracellular fluid sampling collection technique utilizing a perfused semipermeable catheter to permit diffusion of molecules between brain interstitium and the perfusate. We hypothesized that microdialysis may identify a metabolomics-based biomarker response to therapy in IDH1-mutant tumors. To test this hypothesis, orthotopic xenografts were generated from patient-derived xenografts (PDX) harboring mutant IDH-1 (R132H). Perfusates were collected from intra-cranial tumors in athymic nude mice sampled at baseline and 72h post treatment with temozolomide (TMZ), an oral alkylating agent used to treat IDH1-mutant gliomas, compared with vehicle treatment. Perfusates were analyzed via untargeted metabolomic profiling using liquid chromatography-mass spectrometry. Tumor specific metabolites such as (D)-2 hydroxyglutarate, were detected in microdialysate from IDH-1 mutant tumor bearing mice compared to non-tumor bearing mice. We also found high levels of metabolites such as 5-methylthioadenosine, and dimethylarginine and wide range of amino acids in microdialysate from IDH-1 mutant tumor bearing mice. TMZ treatment induced changes to metabolites in creatine and histidine metabolism. Our results indicate that microdialysis is a feasible technology to identify metabolomics-based biomarkers in IDH1-mutant gliomas and their response to therapy. We suggest that in vivo intratumoral microdialysis over several days could yield metabolic pharmacodynamic biomarkers of value to therapeutic translation for IDH-mutant gliomas.
DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
Hirte, Renee, Olson, Ian , Mansour, Moustafa , Ikram, Samar, Munoz-Casabella, Amanda , Warrington, Arthur E. , Mansour, Moustafa A , Rahman, Masum , Sutiwisesak, Rujapope , Carlstrom, Lucas P. , Rajani, Karishma , Sarkaria, Jann N. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | March 25, 2021 | Volume: 3 | Issue: Supplement_1 | Pages: i8-i9

10.1093/noajnl/vdab024.034 Get It

Abstract BACKGROUND NAD+ is required for cell metabolism and DNA repair. It is generated from nicotinic acid (NA) by NAPRT and from Nicotinamide (NAM) by NAMPT. D2HG in IDH-mutant tumors methylates and inactivates NAPRT, increasing dependence on NAMPT. Toxic side effects of NAMPT inhibition can be prevented by NA supplementation in healthy cells without NAPRT methylation. A1326133 is a recently described CNS-penetrant NAMPT inhibitor hypothesized to selectively eliminate IDH-mutant NAPRT-methylated gliomas, likely in combination with other therapies. Our group is looking for biomarkers of drug efficacy to augment individualized therapies. To that end, we sought to identify GBM cell lines with varying sensitivity to NAMPT inhibition. METHODS Human non-immortalized astrocytes and human GBM cell lines were utilized from the Mayo Clinic Glioma patient-derived xenograft resource, including IDH-R132Hmutant lines (GBM164, 196) and IDH-WT lines (GBM6, 12, 76). Cell viability was analyzed after 4days incubation with the NAMPT inhibitor, A1326133 +/- Temozolomide (TMZ) or NA. IC50 for A1326133 was estimated based on intracellular ATP using Cell-Titer-Glo. RESULTS Marked heterogeneity between lines was observed in response to A1326133 +/- NA or TMZ. Sensitive and resistant lines were identified among both IDH-mutant and IDH-WT cell lines. IC50s: GBM164, 12, 6, 196 and 76 were 5.6, 9.3, 39.2, 910, and 9455nM, respectively. NA partially rescued GBM164 by NA (IC50 increased to 20.8nM) but not GBM6 nor 12. IC50 for Human astrocytes was 221.7nM, but >10,000nM with NA. Addition of TMZ did not improve A1326133 efficacy. CONCLUSION Our data illustrate the potential utility of NAMPT inhibition to kill a subset of IDH-WT and IDH mutant lines, but conflict with previously reported TMZ synergy and correlation with mutant IDH. NA may increase safety but could decrease efficacy in certain lines. Ongoing studies seek metabolic biomarkers of therapeutic efficacy to guide individualized therapy with NAMPT inhibitors.
DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
Zhou, Weihua , Yao, Yangyang , Wilder-Romans, Kari , Dresser, Joseph, Werner, Christian K. , Sun, Hanshi, Zaho, Shuang, Davis, Mary A., Halbrook, Christopher J. , Srinivasan, Sudharsan , Jairath, Neil , Correa, Luis O. , Walker, Angela K., Kachman, Maureen , Qi, Nathan , Morgan, Meredith A. , Rehemtulla, Alnawaz , Lawrence, Theodore S. , Lyssiotis, Costas A. , Wahl, Daniel , Lawrence, Theodore S , Lyssiotis, Costas A , Scott, Andrew J. , Pratt, Drew , Sajjakulnukit, Peter , Nelson, Barbara Scott , Zhang, Li , Gatto, Francesco , Umemura, Yoshie , Sarkaria, Jann N. , Xiong, Jianping , Castro, Maria Graciela , Lowenstein, Pedro Ricardo , Chandrasekaran, Sriram

Mayo Clinic

Neuro-Oncology Advances | March 25, 2021 | Volume: 3 | Issue: Supplement_1 | Pages: i11-i11

10.1093/noajnl/vdab024.046 Get It

Abstract Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming radiation (RT) resistance. To discover genotype-independent mediators of RT resistance, we correlated RT resistance with the concentration of approximately 700 metabolites across 23 GBM cell lines. Purine metabolites, especially those containing the base guanine, were most correlated with RT resistance. Similarly, increased abundance of tumor purines was associated with decreased survival in GBM patients treated with RT. This relationship is causal. Purine supplementation protected RT-sensitive GBMs from RT and promoted the repair of RT-induced double strand DNA breaks (DSBs). In vitro and in vivo stable isotope tracing confirmed that GBM cell lines and orthotopic patient-derived xenografts primarily generated purines through the de novo synthetic pathway. RT treatment further increased de novo purine synthesis in GBM through signaling via the DNA damage response. Inhibition of de novo GTP synthesis with mycophenolic acid (MPA) sensitized multiple GBM cell lines and neurospheres to RT by slowing the repair of RT-induced DSBs. MPA-induced radiosensitization was GTP-dependent as it was rescued by nucleoside supplementation. Modulating pyrimidine metabolism affected neither RT resistance nor DSB repair, suggesting these GTP-specific effects are due to active signaling rather than its ability to act as a physical substrate for DNA repair and candidate signaling molecules have been identified. These results were recapitulated in vivo with mycophenolate mofetil (MMF), the orally bioavailable FDA-approved prodrug of MPA. MMF potentiated RT efficacy, reduced tumor guanylates and slowed the repair of RT-induced DSBs across multiple models. Because de novo purine synthesis is activated by many of the oncogenic alterations that drive GBM, its inhibition is a promising genotype-independent strategy to overcome GBM RT resistance. We have now begun a clinical trial to determine whether combining MMF and RT is safe and potentially efficacious in patients with GBM.
The Anesthesiology Milestones 2.0: An Improved Competency-Based Assessment for Residency Training
Walker, Kim, Brennan, Kaitlyn , Jackson, Chelsia, Edgar, Laura , Ellinas, Herodotos , Long, Timothy R. , Trombetta, Carlos , Laskey, Martin G., Wargo, Bradley W, Dainer, Rupa J., Draconi, Crys, Mitchell, John , Ambardekar, Aditee P. , McKenzie-Brown, Anne Marie , Mitchell, John D

Mayo Clinic

Anesthesia & Analgesia | March 25, 2021 | Volume: 133 | Issue: 2 | Pages: 353-361

10.1213/ane.0000000000005499 | PMID 33764340 Get It

The evolution of medical education, from a time-based to a competency-based platform, began nearly 30 years ago and continues to slowly take shape. The development of valid and reproducible assessment tools is the first step. Medical educators across specialties acknowledge the challenges and remain motivated to develop a relevant, generalizable, and measurable system. The Accreditation Council for Graduate Medical Education (ACGME) remains committed to its responsibility to the public by assuring that the process and outcome of graduate medical education in the nation’s residency programs produce competent, safe, and compassionate doctors. The Milestones Project is the ACGME’s current strategy in the evolution to a competency-based system, which allows each specialty to develop its own set of subcompetencies and 5-level progression, or milestones, along a continuum of novice to expert. The education community has now had nearly 5 years of experience with these rubrics. While not perfect, Milestones 1.0 provided important foundational information and insights. The first iteration of the Anesthesiology Milestones highlighted some mismatch between subcompetencies and current and future clinical practices. They have also highlighted challenges with assessment and evaluation of learners, and the need for faculty development tools. Committed to an iterative process, the ACGME assembled representatives from stakeholder groups within the Anesthesiology community to develop the second generation of Milestones. This special article describes the foundational data from Milestones 1.0 that was useful in the development process of Milestones 2.0, the rationale behind the important changes, and the additional tools made available with this iteration.
Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity
Smith, Kelsey M. , Zalewski, Nicholas L. , So, Elson, Cascino, Gregory D. , Ritaccio, Anthony L. , Pittock, Sean J. , Dubey, Divyanshu , Budhram, Adrian , Pittock, S J , Dubey, Divyanshu , Smith, Kelsey M , Britton, Jeffrey W. , So, Elson L., McKeon, Andrew

Mayo Clinic

Epilepsia | March 25, 2021 | Volume: 62 | Issue: 5 | Pages: No page available

10.1111/epi.16888 | PMID 33764529 Get It

AbstractThe objective of this study was to describe serological association of musicogenic epilepsy and to evaluate clinical features and outcomes of seropositive cases. Through retrospective chart review, musicogenic epilepsy patients were identified. Among 16 musicogenic epilepsy patients, nine underwent autoantibody evaluations and all had high‐titer glutamic acid decarboxylase 65–immunoglobulin G (GAD65‐IgG; >20 nmol·L–1, serum, normal ≤ .02 nmol·L–1, eight women). Median GAD65‐IgG serum titer was 294 nmol·L–1 (20.3–3005 nmol·L–1), and median cerebrospinal fluid titer (n = 4) was 14.7 nmol·L–1. All patients had temporal lobe epilepsy, and bitemporal epileptiform abnormalities were common. Right temporal lobe seizures were most frequently captured when seizures were induced by music on electroencephalogram (3/4; 75%). Intravenous (IV) methylprednisolone and/or IV Ig (IVIG) was utilized in four patients, with one having greater than 50% reduction. Rituximab (n = 2) and mycophenolate (n = 1) were ineffective. Two patients underwent right temporal lobe resections but continued to have seizures. Vagus nerve stimulation was effective at reducing seizures in one patient by 50%, and an additional patient was seizure‐free by avoiding provoking music. Right temporal lobe epilepsy was more common among patients with musicogenic epilepsy when compared to nonmusicogenic GAD65 epilepsies (n = 71, 89% vs. 47%, p = .03). GAD65‐IgG should be tested in patients with musicogenic epilepsy, given implications for management and screening for comorbid autoimmune conditions.
Jeffrey B. Geske, MD
Geske, Jeffrey B. , Geske, Jeffrey B

Mayo Clinic

European Heart Journal | March 25, 2021 | Volume: 42 | Issue: 33 | Pages: 3119-3119

10.1093/eurheartj/ehab142 | PMID 33764446 Get It